The HTA review remains shrouded in secrecy, with brief and vaguely worded agendas released after meetings are held, no communiqués published for the past seven meetings, and organisations in other countries knowing more about the options under consideration and seeming to have more input than the Australian community.
But for a few selected insiders, the HTA review is a 'bin fire' of non-transparency
September 11, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Cartherics secures Chinese patent to boost immune cell function in solid tumours
August 27, 2025 - - Australian Biotech -
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 - - Australian Biotech -
Starpharma advances dendrimer platform with clinical, commercial, and strategic progress
August 27, 2025 - - Australian Biotech -
Biome achieves breakthrough year with first profit and rapid global expansion
August 27, 2025 - - Australian Biotech -
Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth
August 27, 2025 - - Australian Biotech -
Sigma Healthcare delivers strong first-year results after Chemist Warehouse merger
August 27, 2025 - - Latest News -
Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push
August 27, 2025 - - Latest News